

ASX Announcement and Media Release

Date: 17 September 2002

PEPTECH US ANTI-TNF PATENT ISSUED

Further to our announcement on 12 September 2002, Peptech announced that patent application number 09/736,792 has been issued today under patent number 6,451,983 entitled "Tumour Necrosis Factor Antibodies" in the USA.

As noted previously, Peptech is confident that the issue of this patent will activate its licence agreement in the USA with Centocor.

About Peptech Limited

Peptech Limited is an Australian biopharmaceutical company, focussed on the development and commercialisation of human therapeutic proteins. Peptech's portfolio of patents covering the use of antibodies and/or antibody fragments that bind to TNF, has been licensed to Centocor, Inc. (a subsidiary of Johnson and Johnson) and Knoll AG (now part of Abbott Laboratories). Under these license agreements, Peptech is to receive ongoing royalties on sales of their products, REMICADE® and D2E7, respectively, in countries in which a valid patent has been issued. European and US marketing approval for D2E7 is expected in 2003.

For further information please contact:

STEPHEN KWIK
MANAGING DIRECTOR
PEPTECH LIMITED
Ph (02) 9870 8788

Dr PAUL SCHOBER
INVESTOR RELATIONS
PEPTECH LIMITED
Ph (02) 9870 8788